Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00652782 | Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients | PHASE2 | COMPLETED | 160 | — | — | Dec 1, 2004 | - | Apr 4, 2008 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | rolofyline 2.5 mg IV QD |
| 2 | EXPERIMENTAL | rolofyline 15 mg IV QD |
| 3 | EXPERIMENTAL | rolofyline 30 mg IV QD |
| 4 | EXPERIMENTAL | rolofyline 60 mg IV QD |
| 5 | PLACEBO_COMPARATOR | placebo for rolofyline IV QD |
| Name | Type | Description |
|---|---|---|
| rolofyline | DRUG | rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days |
| Comparator Placebo (unspecified) | DRUG | Matching placebo for rolofyline IV QD; 3 days |
Inclusion Criteria: * Be able to provide written informed consent, * Be a male or female at least 18 years of age, * Be hospitalized for fluid overload requiring IV diuretic therapy * History of use of diuretic therapy for CHF (including this admission), * Be admitted to the hospital within 36 hour...